Organization | Molecular Templates

Molecular Templates Report issue

For profit Phase 1 Phase 2 Phase 3

Founded: Georgetown TX United States (2000)

Organization Overview

First Clinical Trial

2015

NCT02361346

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Molecular Templates | Molecular Templates, Inc.

Active Ingredients

Drugs in Phase 3 Trials (5)

Key: Molecular Templates (0) Acquired (5)

doxorubicin (Doxil) (3 trials)

evofosfamide (23 trials)

gemcitabine (gemzar) (5 trials)

glufosfamide (4 trials)

lonidamine (2 trials)

Drugs in Phase 2 Trials (9)

Key: Molecular Templates (2) Acquired (7)

89zr-trastuzumab (1 trial)

bortezomib (velcade) (1 trial)

mt-3724 (5 trials)

pemetrexed (alimta) (1 trial)

pomalidomide (pomalyst) (1 trial)

sorafenib (nexavar) (1 trial)

sunitinib (sutent) (1 trial)

tarloxotinib (2 trials)

urea (1 trial)

Drugs in Phase 1 Trials (8)

Key: Molecular Templates (4) Acquired (4)

carboplatin (paraplatin) (1 trial)

d-arabino-2-desoxyhexose (1 trial)

mt-5111 (1 trial)

mt-6402 (1 trial)

mt-8421 (1 trial)

nivolumab (opdivo) (1 trial)

paclitaxel (taxol) (2 trials)

pazopanib (votrient) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Leukemia (Phase 1)

Leukemia, B-Cell (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Leukemia, Lymphoid (Phase 1)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 41
# of Trial APIs: 22